Search for Clinical Trial Results
Germinoma - 51 Studies Found
Status | Study |
Active, not recruiting |
Study Name: Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) Condition:
Date: 2012-09-28 Interventions:
|
Recruiting |
Study Name: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Condition:
|
Completed |
Study Name: Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Condition:
|
Completed |
Study Name: Sunitinib in Treating Young Patients With Refractory Solid Tumors Condition:
Interventions: |
Terminated |
Study Name: Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Condition:
|
Completed |
Study Name: Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Condition:
|
Completed |
Study Name: Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Condition:
|
Completed |
Study Name: Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Condition:
|
Completed |
Study Name: ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors Condition: Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas) Date: 2010-01-21 Interventions: Drug: Tivantinib (ARQ 197) Capsule, 120 mg, BID (360 mg), approximately 112 days |
Completed |
Study Name: Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP) Condition: Dysgerminoma Date: 2005-09-13 Interventions: Drug: Darbepoetin alfa |